Pneumocystis
Experimental TherapeuticsIn Vitro Activity of a Novel Antifungal Compound, MYC-053, against Clinically Significant Antifungal-Resistant Strains of Candida glabrata, Candida auris, Cryptococcus neoformans, and Pneumocystis spp.An urgent need exists for new antifungal compounds to treat fungal infections in immunocompromised patients. The aim of the current study was to investigate the potency of a novel antifungal compound, MYC-053, against the emerging yeast and yeast-like pathogens Candida glabrata, Candida auris,...
SusceptibilitySite-Directed Mutagenesis of the 1,3-β-Glucan Synthase Catalytic Subunit of Pneumocystis jirovecii and Susceptibility Assays Suggest Its Sensitivity to CaspofunginThe echinocandin caspofungin inhibits the catalytic subunit Gsc1 of the enzymatic complex synthesizing 1,3-β-glucan, an essential compound of the fungal wall. Studies with rodents showed that caspofungin is effective against Pneumocystis asci.
SusceptibilityChloroquine Analogues as Leads against Pneumocystis Lung PathogensThe impact of Pneumocystis pneumonia (PcP) on morbidity and mortality remains substantial for immunocompromised individuals, including those afflicted by HIV infection, organ transplantation, cancer, autoimmune diseases, or subject to chemotherapy or corticosteroid-based therapies. Previous work from our group has shown that repurposing antimalarial compounds for PcP...
- Experimental TherapeuticsMechanisms of Action of Vitamin D as Supplemental Therapy for Pneumocystis Pneumonia
- Mechanisms of ResistanceMutations in the Pneumocystis jirovecii DHPS Gene Confer Cross-Resistance to Sulfa Drugs
- Mechanisms of ResistanceMutations of Pneumocystis jirovecii Dihydrofolate Reductase Associated with Failure of Prophylaxis
- Mechanisms of ResistanceGenotypes of Pneumocystis jiroveci Isolates Obtained in Harare, Zimbabwe, and London, United Kingdom